Medpace Stock Forecast, Price & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEDP stock has increased by 34.5% and is now trading at $112.5250.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Monday, October 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings results on Monday, July, 27th. The company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.28. The firm had revenue of $205 million for the quarter, compared to analyst estimates of $181.17 million. Medpace had a net margin of 12.11% and a return on equity of 16.05%. Medpace's revenue was down 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS.
View Medpace's earnings history.

Medpace issued an update on its FY20 earnings guidance on Monday, July, 27th. The company provided earnings per share guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million.

5 analysts have issued 12-month price targets for Medpace's stock. Their forecasts range from $75.00 to $124.00. On average, they expect Medpace's share price to reach $97.67 in the next year. This suggests that the stock has a possible downside of 13.2%.
View analysts' price targets for Medpace.

Medpace saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,390,000 shares, a decline of 14.7% from the August 15th total of 1,630,000 shares. Based on an average daily volume of 314,500 shares, the short-interest ratio is currently 4.4 days. Currently, 5.1% of the company's shares are short sold.
View Medpace's Short Interest.

Some companies that are related to Medpace include PPD (PPD), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Square (SQ), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Intuitive Surgical (ISRG) and Crispr Therapeutics (CRSP).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.26%), Wasatch Advisors Inc. (7.23%), Pendal Group Ltd (3.04%), Boston Trust Walden Corp (1.11%), Fisher Asset Management LLC (1.01%) and Charles Schwab Investment Management Inc. (0.95%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Vanguard Group Inc., Federated Hermes Inc., Bernzott Capital Advisors, MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Sei Investments Co., and AQR Capital Management LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Wasatch Advisors Inc., Charles Schwab Investment Management Inc., Redwood Investments LLC, Nordea Investment Management AB, American Capital Management Inc., ClariVest Asset Management LLC, and Raymond James & Associates.
View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $112.53.

Medpace has a market capitalization of $3.98 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]